Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.
John Fox, MD, MHA, wondered if the FDA’s announcement that it will begin to regulate laboratory-developed tests being marketed will limit the number of people who develop tests and help clean up the market.
Daniel F. Hayes, MD, hopes that will be the case and he is happy with the FDA initiative and how responsibly the agency has approached beginning to regulate the field.
“There’s a great deal of concern that this will squash innovation and dampen down new test development,” he said. “I think it might have the opposite [effect].”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More